Skip to content

Comparison Efficacy in Patients With Asthma Using Foster MDI and Relvar Medications

Comparison Efficacy in Patients With Asthma Using Foster MDI and Relvar Medications

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04185129
Enrollment
200
Registered
2019-12-04
Start date
2020-01-01
Completion date
2022-06-30
Last updated
2019-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Brief summary

This is a randomized study to compare asthma patients using Foster or Relvar.

Detailed description

The Global Asthma Association (GAA) and the World Allergy Organization (WAO) recently issued statements stating that the small airway is caused by asthma and chronic obstructive pulmonary disease (COPD). Both pathogenesis and treatment play an important role. The small airway is an airway with diameter less than 2 mm and is one of the main sites where airflow obstruction occurs. Small particles (\<2 μm) and large particles are more likely to deposit in the distal airways, and have shown to have better effects on asthma and pulmonary obstruction. At the same time, real-life research has also shown that extra-fine particles provide better asthma control than large particles, and can better improve quality of life.The aim of the study is to compare the efficacy of asthma inhalers between extra-fine particles and non-extra-fine particles.

Interventions

DRUGFoster

a randomized study for comparison asthma patients using Foster or Relvar. The primary end point is lung function improvement evaluation

Sponsors

Orient Europharma Co., Ltd.
CollaboratorINDUSTRY
Far Eastern Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients diagnosis with asthma with treatment naive * asthma patients with poor controlled status

Exclusion criteria

* COPD * smoking history * pregnancy * cardiaovascular disease * patients with acute respiratory infection

Design outcomes

Primary

MeasureTime frameDescription
Lung function improvementone yearFEV1

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026